Ikarian Capital’s Ginkgo Bioworks DNA Stock Holding History

Ikarian Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-58,300	Closed	-$332K	–	153
2025 Q1	$332K	Buy	+58,300	New	+$594K	0.04%	125

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ikarian Capital's DNA Position: Q2 2025 in Review

Ikarian Capital sold out of Ginkgo Bioworks (DNA) in Q2 2025, closing a stake of 58,300 shares — an estimated $332K sold.

Ikarian Capital first reported a position in DNA in Q1 2025 and held it in 1 quarter. The position peaked at $332K in Q1 2025. 166 funds tracked by Wall St. Rank hold DNA as of Q2 2025.

Ikarian Capital reported no remaining Ginkgo Bioworks position as of Q2 2025 after selling out during the quarter.
Ikarian Capital sold 58,300 Ginkgo Bioworks shares in Q2 2025, an estimated $332K.
Ikarian Capital first reported a position in Ginkgo Bioworks in Q1 2025 and held it in 1 quarter.
Ikarian Capital's Ginkgo Bioworks position peaked at $332K in Q1 2025.
166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.